A Study to Assess the Efficacy, Safety and Tolerability of AT673 Co-administered With Semaglutide in Adult Participants With Type 2 Diabetes (T2D) and Overweight or Obesity
NCT07724340 on ClinicalTrials.gov · last registry update 2026-09-01
Recruiting now, toward 150 participants. Due to report February 2027, alongside 30 other tracked readouts that quarter. Primary outcome, as filed: Body weight. Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.
- Status
- RECRUITING
- Phase
- P2
- Drug
- semaglutideRybelsus, Wegovy, Ozempic
- Sponsor
- Antag Therapeutics
- Sponsor type
- Industry
- Enrollment
- 150
- Started
- 2026-06-19
- Primary completion
- 2027-02 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Body weight
Conditions studied
Adults With Overweight/Obesity and Type 2 Diabetes
Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.